Company Directory - Research & Development

CSL Behring has grown into a global biotechnology leader, driven by the promise to save and improve lives. We offer the broadest range of quality plasma-derived and recombinant therapies in our industry. Our ability to innovate and deliver life-saving medicines for patients with rare disease and other unmet medical needs around the world has earned us a reputation for always putting patients first.

A first-of-its-kind therapeutics company that is discovering and developing medicines by studying and altering cell behaviors. Cellarity has developed a powerful, generalizable platform harnessing single-cell technologies and machine learning to unveil the network state of a given cell, defining the cell's behavior.

Cenix BioScience is a contract research organization focused on the discovery and pre-clinical development of novel therapeutics, specializing in advanced applications of RNA interference (RNAi) gene silencing combined with high content phenotyping in cultured cells in vitro and in animals in vivo.

Century Therapeutics is an innovative biotechnology company utilizing a comprehensive cell therapy platform to develop transformative allogeneic cell therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies.

Cherry biolabs was founded in 2019 as a Spin-off from the University Hospital of Würzburg with a focus on biotechnology and immunotherapy target validation. The company holds the exclusive license for the Hemibody platform technology granted by the University Würzburg.

We are an international company based in Parma, with more 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas.

Children’s Cancer Institute is the only independent medical research institute in Australia wholly dedicated to curing childhood cancer. Cancer kills more children than any other disease, so our research is critical. With the brightest brains, cutting-edge facilities, and the greatest determination, we will get the job done.

Clene is revolutionizing the treatment of neurodegenerative disease with an innovative nanotherapeutic platform to generate first-in-class elemental nanomedicines designed to optimize neurorepair and health through energy-enhancing bioenergetic catalysis.

Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancer diagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase.

Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.

Coave Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases. Coave Therapeutics’ next-generation AAV-Ligand Conjugate (‘ALIGATER’) platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases. The company is advancing a pipeline of novel therapies targeting CNS and eye diseases where targeted gene therapy using chemically modified AAVs (coAAVs) has the potential to be most effective. Coave Therapeutics, which is headquartered in Paris (France), is backed by leading international life science and strategic investors Seroba Life Sciences, Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital and Sham Innovation Santé/Turenne.

Our mission is to apply our breakthroughs in automation solutions for DNA, RNA, and protein synthesis to enable customers to program and "write" synthetic biology that creates sustainable healthcare and technology solutions for some of humanity’s biggest challenges.

For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions, and the clinical care needs of physicians and patients around the world. We provide rapid, reliable and highly sensitive computerized cognitive tests and support electronic clinical outcome assessment (eCOA) solutions.

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings.

Corcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998. Corcept is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical needs related to excess cortisol activity.

Crescendo Biologics (Crescendo) is a clinical stage company, focused on transforming the lives of cancer patients through its pipeline of novel, T cell enhancing therapies. The lead programme, CB307, is a first in class PSMA x CD137 (4-1BB) bispecific molecule.

CrownBio is a Cutting-Edge Translational Technology Company Making Precision Medicine a Reality. CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology and inflammation.

We are pioneering the development of a completely new class of drugs based on the messenger RNA (mRNA) molecule. The basic principle is the use of this molecule as a data carrier for information, with the help of which the body can produce its own active ingredients for fighting various diseases.

Curia is a global contract research, development and manufacturing organization (CDMO), offering products and services across the drug development spectrum to help our partners turn their ideas into real-world impact. We partner closely with pharmaceutical and biotechnology companies to boost business performance and improve patients’ lives.

Founded in 2017 by Flagship Pioneering, Cygnal Therapeutics is the first company to build a platform to develop drugs in the field of exoneural biology. Exoneural biology is broadly implicated in human health and disease. We are creating new medicines across multiple therapeutic areas, starting with cancer and inflammatory diseases.